Portal Hypertension
Portal hypertension is an abnormal increase in pressure within the portal venous system, the network of veins that carries blood from the digestive organs and spleen to the liver. It is most often caused by cirrhosis but can also result from conditions affecting the portal vein itself, the liver tissue, or the veins leaving the liver. Portal hypertension is responsible for many of the most serious complications of chronic liver disease, including varices, variceal bleeding, ascites, hepatic encephalopathy, and enlarged spleen with low platelets. Imaging—particularly ultrasound, CT, MRI, and elastography—plays a central role in diagnosis and monitoring.
What is it?
The portal venous system is a specialized network of veins that carries blood from the digestive organs (stomach, intestines, spleen, gallbladder, and pancreas) to the liver. Most of the blood the liver receives—about 75 percent—comes from this portal system, while the rest comes from the hepatic artery. The liver processes nutrients, hormones, medications, and toxins from this blood and then returns it through the hepatic veins to the inferior vena cava and the heart. Portal hypertension is an abnormal increase in the pressure within the portal vein and its branches, defined more precisely by an elevated pressure gradient between the portal vein and the systemic veins.
Portal hypertension is classified by where the resistance to blood flow occurs. Prehepatic (before the liver) causes include portal vein thrombosis, portal vein compression by tumors or lymph nodes, and congenital abnormalities of the portal vein. Intrahepatic (within the liver) causes are by far the most common and are subdivided into presinusoidal (such as schistosomiasis and certain biliary diseases), sinusoidal (such as cirrhosis from any cause, which is the leading cause overall), and postsinusoidal (such as sinusoidal obstruction syndrome). Posthepatic (after the liver) causes include Budd-Chiari syndrome (blockage of the hepatic veins), inferior vena cava obstruction, and severe right-sided heart failure or constrictive pericarditis. Identifying the underlying cause is central to management because treatment is directed at the specific mechanism.
When pressure in the portal system rises, blood seeks alternative routes back to the heart through smaller veins that connect the portal and systemic venous systems. Over time, these “collateral” veins enlarge into varices, most notably in the esophagus and stomach but also in the rectum, around the umbilicus, and elsewhere. Variceal bleeding from esophageal or gastric varices is one of the most serious complications of portal hypertension and remains an important cause of hospitalization and mortality in patients with advanced liver disease. Other complications include ascites (fluid accumulation in the abdomen), hepatic encephalopathy (brain dysfunction related to liver failure and portosystemic shunting), spontaneous bacterial peritonitis (infection of ascitic fluid), hepatorenal syndrome (kidney dysfunction in advanced liver disease), hepatopulmonary syndrome, portopulmonary hypertension, enlarged spleen with low platelet counts, and increased susceptibility to infections.
Many patients with mild or early portal hypertension have no symptoms, and the condition is suspected because of an enlarged spleen, low platelet counts, or abnormal imaging findings. As pressure rises and complications develop, symptoms may include progressive abdominal swelling, leg swelling, fatigue, weight loss, easy bruising or bleeding, confusion or sleep changes, itching, jaundice, and gastrointestinal bleeding. Variceal bleeding can present with vomiting blood, coffee-ground material, or passing black, tarry stools (melena), and can be life-threatening. Sudden worsening of mental status, severe leg swelling with shortness of breath, fever, or signs of severe infection or shock can indicate serious decompensation requiring urgent care.
Diagnosis combines clinical assessment, blood tests, imaging, and—in selected cases—direct pressure measurements. Blood tests typically show signs of advanced liver disease (such as low albumin, prolonged INR, low platelets, and abnormal liver enzymes) and may show signs of complications. Ultrasound with Doppler is often the first imaging study and can show liver and spleen size, ascites, signs of cirrhosis, portal vein patency, and altered blood flow patterns. CT and MRI provide more detailed information and are particularly useful for evaluating collateral veins, portal vein thrombosis, focal liver lesions, vascular anatomy, and surrounding structures. Elastography (using ultrasound such as FibroScan or MR elastography) can help assess liver and spleen stiffness, which correlate with portal pressure in many patients. Endoscopy is used to screen for and treat varices in the esophagus and stomach. In specialized centers, measurement of the hepatic venous pressure gradient (HVPG) by an interventional radiology team provides the most precise assessment of portal pressure and helps guide management in selected patients.
Important to Know
Management of portal hypertension focuses on three goals: treating the underlying cause, preventing and managing complications, and—when appropriate—considering definitive treatments such as liver transplantation. Care is typically coordinated by hepatologists, gastroenterologists, interventional radiologists, surgeons, and primary care clinicians, with input from infectious disease, nephrology, cardiology, and palliative care as needed.
Treatment of the underlying cause is fundamental. For cirrhosis from steatotic liver disease (MASLD/MASH), this includes weight loss, regular activity, control of diabetes and lipid abnormalities, treatment of sleep apnea, and limiting alcohol; in selected patients, newer disease-modifying medications may be available. For alcohol-related liver disease, abstinence is the single most important intervention, along with support for alcohol use disorder. For chronic viral hepatitis, effective antiviral therapy can dramatically improve outcomes—hepatitis C is now curable in most patients with direct-acting antivirals, and hepatitis B is managed long-term with effective antivirals. Autoimmune, metabolic, and biliary causes have their own specific treatments. For vascular causes such as portal vein thrombosis or Budd-Chiari syndrome, anticoagulation and—in selected cases—catheter-based or surgical interventions are important.
Prevention and management of complications are essential. Nonselective beta-blockers (such as propranolol, nadolol, or carvedilol) are commonly used to reduce portal pressure and decrease the risk of variceal bleeding. Endoscopic variceal band ligation is used to prevent first bleeding from high-risk varices and to treat acute and recurrent variceal bleeding. Diuretics (such as spironolactone and furosemide) combined with sodium restriction are mainstays of ascites management; large-volume paracentesis with albumin may be needed for refractory ascites. Antibiotic prophylaxis is used to reduce the risk of spontaneous bacterial peritonitis in selected patients. Lactulose and rifaximin are used to treat and prevent hepatic encephalopathy. Vaccinations against hepatitis A and B, influenza, pneumococcal infection, COVID-19, and other infections are important.
Transjugular intrahepatic portosystemic shunt (TIPS) is a catheter-based procedure that creates a new channel between the portal and hepatic veins inside the liver, reducing portal pressure. TIPS is used in selected patients with refractory variceal bleeding, refractory ascites, or other specific complications, and decisions about TIPS take into account the risk of hepatic encephalopathy and other factors. Surgical shunts and devascularization procedures are used less commonly today.
Liver transplantation is the ultimate treatment for advanced liver disease and portal hypertension and offers the potential for long-term recovery and good quality of life in carefully selected patients. Evaluation for transplantation is performed in specialized centers.
Surveillance for hepatocellular carcinoma—typically with periodic imaging, often combined with alpha-fetoprotein testing—is recommended in patients with cirrhosis and in other high-risk groups, since early detection significantly improves outcomes. Patients with portal hypertension also benefit from monitoring for kidney dysfunction, anemia, malnutrition, sarcopenia, and bone health.
Patient education is important. Understanding the disease, recognizing warning signs of bleeding, infection, or hepatic encephalopathy, careful use of medications and supplements (since many are metabolized by the liver), abstaining from alcohol, and importance of follow-up all contribute to better outcomes.
Red flag symptoms include vomiting blood or coffee-ground material; black, tarry stools or rectal bleeding; severe abdominal swelling with shortness of breath, fever, or pain; severe confusion, lethargy, or difficulty arousing; signs of infection (fever, chills, severe weakness); rapidly progressive jaundice; severe leg swelling with shortness of breath; or signs of shock. These warrant immediate emergency evaluation, as they may indicate life-threatening complications of portal hypertension.